Full-Time

Molecular Technologist I-IV

Updated on 3/13/2025

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

No salary listed

Junior, Mid

Company Historically Provides H1B Sponsorship

Durham, NC, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • One of the following educational requirements: MS in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year pertinent clinical laboratory experience with molecular biology
  • BS/BA in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year of pertinent clinical lab experience in molecular biology
  • Excellent communication skills
  • Thrives in a fast-paced environment
  • Ability to work with others to plan and carry out scientific programs
  • Self-driven and works well in an interdisciplinary team with minimal direction
  • Strong desire to build products that will save lives and change the course of cancer
  • Impeccable attention to detail
Responsibilities
  • Work with a cutting-edge genomics workflow to provide high-quality next-generation sequencing data with rapid turnaround times in a clinical laboratory.
  • Perform routine testing, quality control, calibration, maintenance and proficiency testing in accordance with current laboratory procedures.
  • Perform complex molecular-based procedures with a high degree of quality and in accordance with established protocols.
  • Perform next-generation sequencing, including nucleic acid extraction, DNA/RNA quantification and qualification, NGS library preparation, probe hybridization, probe/library capture, library cleanup and quantification, loading sequencing libraries onto the Illumina Nextseq, HiSeq4000, and Novaseq.
  • Sterilizing laboratory equipment and workspaces as assigned.
  • Entering clinical patient data into the Laboratory Information Management system.
  • Obtain 12 continuing education hours in the field of oncology or molecular biology.
  • Maintain competency to perform all assigned molecular biology protocols in accordance with CAP, CLIA, NYSDOH regulations.
  • Work the Sunday-Wednesday, AM Shift
Desired Qualifications
  • Experience with next-generation sequencing
  • Work in a CLIA/CAP high-complexity laboratory
  • Experience with robotics and automated liquid handling systems
  • Knowledge of LIMS platforms and various computer systems

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus also conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on personalized medicine, aiming to improve care and treatment options for patients.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Deep 6 AI expands Tempus' network to over 30 million patients.
  • Partnerships with pharmaceutical firms enhance Tempus' collaboration opportunities.
  • AI-driven personalized medicine trends support Tempus' niche expansion in rare diseases.

What critics are saying

  • Integration challenges with Deep 6 AI could disrupt operations if not managed well.
  • $560 million debt financing increases financial risk if revenue growth lags.
  • Olivia app launch may face privacy concerns and regulatory scrutiny.

What makes Tempus unique

  • Tempus uses AI to provide personalized therapy options for cancer patients.
  • Their platform integrates clinical and molecular data for precise treatment recommendations.
  • Tempus' AI-driven insights assist in drug development and patient care optimization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Tempus
Mar 12th, 2025
Tempus Announces Acquisition of Deep 6 AI | Tempus AI

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO --(BUSINESS WIRE)--Mar. 11, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision

TipRanks
Mar 12th, 2025
Tempus AI (TEM) Strengthens Precision Medicine with Deep 6 AI Deal, Cathie Wood Buys the Dip

Tempus AI has acquired Deep 6 AI to expand its reach and enhance offerings in precision medicine.

Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression